Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 26 May 2022.
Search results
204 results
-
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Fezolinetant for menopause-related vasomotor symptoms [ID5071]
Awaiting development [GID-TA10953] Expected publication date: TBC
-
Canakinumab for untreated Schnitzler syndrome [ID4063]
Awaiting development [GID-TA10952] Expected publication date: TBC
-
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593
Awaiting development [GID-TA10957] Expected publication date: TBC
-
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Awaiting development [GID-TA10723] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Awaiting development [GID-TA10728] Expected publication date: TBC
-
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Awaiting development [GID-TA10747] Expected publication date: TBC
-
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Awaiting development [GID-TA10748] Expected publication date: TBC
-
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Awaiting development [GID-TA10750] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Awaiting development [GID-TA10741] Expected publication date: TBC
-
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]
Awaiting development [GID-TA10821] Expected publication date: TBC
-
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Awaiting development [GID-TA10720] Expected publication date: TBC
-
Liposomal bupivacaine for treating postoperative pain [ID3799]
Awaiting development [GID-TA10681] Expected publication date: TBC
-
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)
Awaiting development [GID-TA10306] Expected publication date: TBC
-
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)
Awaiting development [GID-TA10426] Expected publication date: TBC
-
Rivaroxaban for treating chronic heart failure [ID1462]
Awaiting development [GID-TA10393] Expected publication date: TBC
-
Dulaglutide for treating type 2 diabetes [ID1451]
Awaiting development [GID-TA10439] Expected publication date: TBC
-
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]
Awaiting development [GID-TA10861] Expected publication date: TBC
-
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]
Awaiting development [GID-TA10795] Expected publication date: TBC
-
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Awaiting development [GID-TA10716] Expected publication date: TBC
-
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Awaiting development [GID-TA10843] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Awaiting development [GID-TA10848] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]
Awaiting development [GID-TA10683] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Awaiting development [GID-TA10895] Expected publication date: TBC
-
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]
Awaiting development [GID-TA10896] Expected publication date: TBC
-
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]
Awaiting development [GID-TA10897] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Awaiting development [GID-TA10779] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Awaiting development [GID-TA10778] Expected publication date: TBC
-
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]
Awaiting development [GID-TA10718] Expected publication date: TBC
-
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer [ID4034]
Awaiting development [GID-TA10925] Expected publication date: TBC
-
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Awaiting development [GID-TA10926] Expected publication date: TBC
-
Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]
Awaiting development [GID-TA10927] Expected publication date: TBC
-
Quizartinib for untreated FLT3-ITD-positive acute myeloid leukaemia [ID4042]
Awaiting development [GID-TA10928] Expected publication date: TBC
-
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]
Awaiting development [GID-TA10929] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID4044]
Awaiting development [GID-TA10930] Expected publication date: TBC
-
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma when a stem cell transplant has failed or is unsuitable [ID4045]
Awaiting development [GID-TA10931] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
Awaiting development [GID-TA10933] Expected publication date: TBC
-
Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]
Awaiting development [GID-TA10934] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
Awaiting development [GID-TA10935] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]
Awaiting development [GID-TA10814] Expected publication date: TBC
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Awaiting development [GID-TA10668] Expected publication date: TBC
-
Dostarlimab with carboplatin and paclitaxel for treating recurrent or advanced endometrial cancer [ID3968]
Awaiting development [GID-TA10850] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Awaiting development [GID-TA10851] Expected publication date: TBC
-
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Awaiting development [GID-TA10773] Expected publication date: TBC
-
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [ID3971]
Awaiting development [GID-TA10860] Expected publication date: TBC
-
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Awaiting development [GID-TA10905] Expected publication date: TBC
-
Cemiplimab with chemotherapy for untreated advanced or metastatic non-small-cell lung cancer [ID3949]
Awaiting development [GID-TA10907] Expected publication date: TBC
-
Pralsetinib for thyroid cancer [ID4018]
Awaiting development [GID-TA10910] Expected publication date: TBC
-
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]
Awaiting development [GID-TA10911] Expected publication date: TBC